Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$106.72 +0.5%	$102.63	$76.53 ▼ $131.49	$25.65B	1.29	942,093 shs	490,569 shs
MRK Merck & Co., Inc.	$78.93 +0.1%	$79.04	$73.31 ▼ $132.29	$198.20B	0.38	13.33 million shs	60.17 million shs
MRNA Moderna	$27.16 -1.4%	$26.36	$23.15 ▼ $129.39	$10.50B	1.86	8.54 million shs	11.54 million shs
NVAX Novavax	$6.37 -2.0%	$6.75	$5.01 ▼ $17.81	$1.03B	2.8	6.34 million shs	3.79 million shs
PFE Pfizer	$24.20 -0.2%	$23.42	$20.92 ▼ $31.54	$137.56B	0.57	41.29 million shs	39.50 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+1.28%	+1.67%	+7.70%	+11.79%	+28.62%
MRK Merck & Co., Inc.	-1.01%	-0.41%	+1.85%	-11.49%	-39.97%
MRNA Moderna	+2.53%	+8.43%	+2.91%	-11.50%	-77.51%
NVAX Novavax	+0.31%	+3.17%	-11.92%	-7.14%	-50.42%
PFE Pfizer	+0.06%	+1.80%	+2.94%	-3.56%	-11.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	2.3151 of 5 stars	4.4	2.0	0.0	0.0	1.3	0.8	0.0
MRK Merck & Co., Inc.	4.9948 of 5 stars	3.2	3.0	5.0	3.9	3.0	2.5	3.8
MRNA Moderna	4.5365 of 5 stars	4.0	2.0	0.0	4.6	1.4	2.5	1.3
NVAX Novavax	4.4635 of 5 stars	3.1	2.0	0.0	4.7	1.3	0.8	3.1
PFE Pfizer	4.866 of 5 stars	2.3	3.0	4.2	4.3	2.9	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.83	Moderate Buy	$137.86	29.18% Upside
MRK Merck & Co., Inc.	2.43	Hold	$109.19	38.33% Upside
MRNA Moderna	2.04	Hold	$46.61	71.62% Upside
NVAX Novavax	2.29	Hold	$17.00	166.88% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	20.54% Upside

Current Analyst Ratings Breakdown

Latest MRNA, PFE, BNTX, NVAX, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$138.00
6/17/2025	NVAX Novavax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00
6/16/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$145.00 ➝ $138.00
6/5/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$134.00 ➝ $145.00
6/3/2025	BNTX BioNTech	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$151.00 ➝ $155.00
6/2/2025	BNTX BioNTech	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$112.00
6/2/2025	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
5/29/2025	BNTX BioNTech	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Neutral	$110.00
5/22/2025	BNTX BioNTech	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$120.00 ➝ $116.00
5/22/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$134.00 ➝ $134.00
5/22/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$33.00 ➝ $26.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.98B	8.62	N/A	N/A	$87.61 per share	1.22
MRK Merck & Co., Inc.	$64.17B	3.09	$9.37 per share	8.42	$18.33 per share	4.31
MRNA Moderna	$3.24B	3.25	N/A	N/A	$28.33 per share	0.96
NVAX Novavax	$682.16M	1.51	N/A	N/A	($3.89) per share	-1.64
PFE Pfizer	$63.63B	2.16	$4.35 per share	5.56	$15.62 per share	1.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$719.92M	-$3.40	N/A	N/A	N/A	-27.37%	-3.94%	-3.41%	8/4/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	11.49	7.97	0.83	27.27%	43.23%	17.11%	7/29/2025 (Estimated)
MRNA Moderna	-$3.56B	-$8.73	N/A	N/A	N/A	-105.67%	-28.69%	-21.94%	7/30/2025 (Estimated)
NVAX Novavax	-$187.50M	$2.65	2.40	79.63	0.06	38.14%	-115.51%	29.99%	8/14/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.53	7.99	0.88	12.62%	20.33%	8.53%	8/5/2025 (Estimated)

Latest MRNA, PFE, BNTX, NVAX, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	NVAX Novavax	$0.71	$2.93	+$2.22	$2.93	$204.08 million	$666.66 million
5/1/2025	Q1 2025	MRNA Moderna	-$2.92	-$2.52	+$0.40	-$2.52	$130.35 million	$108.00 million
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
MRK Merck & Co., Inc.	$3.24	4.10%	N/A	47.16%	14 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	7.11%	N/A	124.64%	16 Years

Latest MRNA, PFE, BNTX, NVAX, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	10.18	10.02
MRK Merck & Co., Inc.	0.69	1.41	1.16
MRNA Moderna	N/A	4.22	4.14
NVAX Novavax	N/A	2.06	2.03
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
MRK Merck & Co., Inc.	76.07%
MRNA Moderna	75.33%
NVAX Novavax	53.04%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
MRK Merck & Co., Inc.	0.13%
MRNA Moderna	11.00%
NVAX Novavax	1.00%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	6,772	240.39 million	194.24 million	Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable
MRNA Moderna	5,800	386.74 million	344.20 million	Optionable
NVAX Novavax	1,990	161.97 million	160.35 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

MRNA, PFE, BNTX, NVAX, and MRK Headlines

Recent News About These Companies

5 Recession-Proof Dividend Stocks With Yields Over 6%

3 hours ago | 247wallst.com

Pfizer's bleeding disorder therapy succeeds in trial with patients with certain antibodies

3 hours ago | msn.com

Pfizer’s New Clinical Study on PF-07985631: A Potential Game-Changer for Kidney Disease

June 27 at 12:56 PM | tipranks.com

Pfizer’s Prevnar 20 Study: A Potential Game-Changer for Elderly Pneumonia Prevention

June 27 at 12:09 PM | tipranks.com

PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal

June 27 at 12:00 PM | zacks.com

Pfizer Inc. (NYSE:PFE) Shares Purchased by Philip James Wealth Mangement LLC

June 27 at 8:17 AM | marketbeat.com

Quilter Plc Reduces Stake in Pfizer Inc. (NYSE:PFE)

June 27 at 8:06 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Purchased by Artemis Investment Management LLP

June 27 at 7:55 AM | marketbeat.com

Pfizer Reveals Positive Phase 3 Results for HYMPAVZI

June 27 at 7:33 AM | miragenews.comM

Pfizer Inc. (NYSE:PFE) Shares Sold by Transcend Capital Advisors LLC

June 27 at 7:25 AM | marketbeat.com

Trust Co. of Vermont Sells 41,031 Shares of Pfizer Inc. (NYSE:PFE)

June 27 at 7:16 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Purchased by Sequoia Financial Advisors LLC

June 27 at 5:01 AM | marketbeat.com

SOL Capital Management CO Sells 28,814 Shares of Pfizer Inc. (NYSE:PFE)

June 27 at 4:52 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Receives Average Recommendation of "Moderate Buy" from Analysts

June 27 at 2:23 AM | marketbeat.com

Top stock price forecast: Plug Power, Uber, and Pfizer

June 27 at 2:02 AM | msn.com

Pfizer's hemophilia drug Hympavzi notches phase 3 win as pharma eyes label expansion

June 27 at 2:02 AM | fiercepharma.comF

Pfizer (NYSE:PFE) Announces Positive Results For Hemophilia Treatment And Declares $0.43 Dividend

June 26 at 9:02 PM | uk.finance.yahoo.com

Pfizer releases positive Hympavzi Phase III results in hemophilia

June 26 at 9:02 PM | thepharmaletter.comT

Pfizer’s Hemophilia Drug Meets Goals In Late-Stage Trial In Patients With Certain Antibodies

June 26 at 9:02 PM | msn.com

All You Need to Know About Pfizer (PFE) Rating Upgrade to Buy

June 26 at 1:01 PM | zacks.com

Pfizer’s Phase 3 Study on Elranatamab: A Potential Game-Changer for Multiple Myeloma Treatment

June 26 at 12:40 PM | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRNA, PFE, BNTX, NVAX, and MRK Company Descriptions

BioNTech NASDAQ:BNTX

$106.72 +0.58 (+0.55%)

Closing price 04:00 PM Eastern

Extended Trading

$106.08 -0.64 (-0.60%)

As of 06:02 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Merck & Co., Inc. NYSE:MRK

$78.93 +0.10 (+0.13%)

Closing price 03:59 PM Eastern

Extended Trading

$79.14 +0.21 (+0.27%)

As of 06:27 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Moderna NASDAQ:MRNA

$27.16 -0.38 (-1.38%)

Closing price 04:00 PM Eastern

Extended Trading

$27.15 -0.01 (-0.04%)

As of 06:29 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Novavax NASDAQ:NVAX

$6.37 -0.13 (-2.00%)

Closing price 04:00 PM Eastern

Extended Trading

$6.38 +0.01 (+0.24%)

As of 06:21 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Pfizer NYSE:PFE

$24.20 -0.04 (-0.18%)

Closing price 03:59 PM Eastern

Extended Trading

$24.18 -0.01 (-0.05%)

As of 06:29 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time